Analyst Research Report Snapshot

Title:

ZEALAND PHARMA - RIDING ON LANTUS’ BACK

Price:

$10.00

Provider:

Edison Investment Research

Date:

28 Nov 2012

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ZELA.CO

Available for Immediate Download
Summary:

The recent CHMP positive opinion for Lyxumia (lixisenatide), its expected US NDA filing next month and the potential EU approval in Q113, create a likely hat trick of positive catalysts. However, a focus on monotherapy overlooks the fact that Zealand’s prospects rely more heavily on the “Fixflex” Lyxumia/Lantus combination. This is falling behind Novo Nordisk’s competing pairing of Tresiba (insulin degludec) – itself newly launched as monontherapy – with Victoza. This, combined with the relative advantages of Tresiba over Lantus, may constrain its commercial potential.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.